Exclusive LifeVantage U.S. Patents
Protandim is protected by four patents. Its patents protect the product from patent infringement--another party duplicating its formula and then creating and marketing an identical product. Every time a new patent is issued, Protandim, The Nrf2 Synergizer, is protected for an extended and additional period of time.
Protandim is protected by 4 U.S. patents:
1st Patent
Patent No. 7,241,461 was granted July 10, 2007. "Compositions And Methods For Alleviating Inflammation And Oxidative Stress In A Mammal." This is a composition patent. # 7,241,461
2nd Patent
Patent No. 7,384,655 was granted June 10, 2008. "Preparation of Compositions to Alleviate Inflammation And Oxidative Stress In A Mammal." This patent is a continuation of the first patent. # 7,384,655
3rd Patent
Patent No. 7,579,026 was granted Aug. 25, 2009. "Methods for Enhancing Antioxidant Enzyme Activity And Reducing C-Reactive Protein Levels." This patent is a divisional patent because it addresses method rather than composition. # 7,579,026
4th Patent
Patent No. 7,923,045 was granted on April 12, 2011. "Compositions For Alleviating Inflammation And Oxidative Stress In A Mammal." This patent is a continuation of the first patent. # 7,923,045
1st Patent
Patent No. 7,241,461 was granted July 10, 2007. "Compositions And Methods For Alleviating Inflammation And Oxidative Stress In A Mammal." This is a composition patent. # 7,241,461
2nd Patent
Patent No. 7,384,655 was granted June 10, 2008. "Preparation of Compositions to Alleviate Inflammation And Oxidative Stress In A Mammal." This patent is a continuation of the first patent. # 7,384,655
3rd Patent
Patent No. 7,579,026 was granted Aug. 25, 2009. "Methods for Enhancing Antioxidant Enzyme Activity And Reducing C-Reactive Protein Levels." This patent is a divisional patent because it addresses method rather than composition. # 7,579,026
4th Patent
Patent No. 7,923,045 was granted on April 12, 2011. "Compositions For Alleviating Inflammation And Oxidative Stress In A Mammal." This patent is a continuation of the first patent. # 7,923,045
